This recombinant monoclonal antibody is developed as a research-grade biosimilar to Telikibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines in type 2 inflammatory responses. Upon ligand binding, IL4R initiates JAK-STAT signaling cascades that promote Th2 cell differentiation, IgE class switching, and the production of inflammatory mediators. Dysregulated IL4R signaling plays a central role in allergic diseases, atopic dermatitis, asthma, and certain fibrotic conditions, making it an important therapeutic target for type 2 inflammation-driven disorders.
Telikibart is a clinical-stage therapeutic antibody designed to block IL4R signaling by preventing both IL-4 and IL-13 from binding to their receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immune responses, and exploring mechanisms underlying allergic and inflammatory diseases. It supports studies in immunology, dermatology, and respiratory research where IL4R antagonism is of scientific interest.
Email: support@cusabio.com
Distributors Worldwide